comparative evaluation of oral voriconazole and oral ketoconazole in severe fungal keratitis

comparative evaluation of oral voriconazole and oral ketoconazole as an adjunct to topical natamycin in severe fungal keratitis

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2016/07/007103

Enrollment

Registered

2016-07-18

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- severe fungal keratitis Health Condition 2: H169- Unspecified keratitis

Interventions

Intervention1: ARM 1 - ORAL VORICONAZOLE ARM 2- ORAL KETOCONAZOLE: ARM1-TOPICAL NATAMYCIN WITH ORAL VOICONAZOE ARM2-TOPICAL NATAMYCIN WITH ORAL KETOCONAZOLE Control Intervention1: nil: nil

Eligibility

Inclusion criteria

Inclusion criteria: SEVERE FUNGAL KERATITIS EVIDENCE OF FUNGI IN SMEAR OR CULTURE VN CONSENT WILLING TO BE TREATED AS INPATIENT AND RETURN IN 3 DAYS TILL EPITHELIZATION

Exclusion criteria

Exclusion criteria: EVIDENCE OF BACTERIA OR ACANTHAMOEBA ON STAIN EVIDENCE OF HERPETIC KERATITIS B/L OR PERFORATED ULCER H/O PREVIOUS OCULAR SX PREGNANCY IMMMUNOCOMPROMISED

Design outcomes

Primary

Measure	Time frame
VISUAL ACUITYTimepoint: DAY3,7,14,21,28,3 MNTHS	—

Secondary

Measure	Time frame
TEAR FILM CONCENTRATION OF DRUG SENSITIVITY AGENTS DRUG SENSITIVITY PATTERNTimepoint: DAY7,14,21	—

Countries

India

Contacts

Public Contactdeepali singhal

R P Centre for Ophthalmic Sciences

deepali.singhal88@gmail.com919868968813

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026